StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Here is a head-scratcher for IR to answer.

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron Dec 30, 2020 12:34am

205 Views

Post# 32195141

RE:RE:Here is a head-scratcher for IR to answer.

What's the market cap of this copy cat rip off company.

Thehuntsman wrote: Good job Nailz. Where the hell did you find this turd?

Nailbiter1 wrote:
About Bionexus Gene Lab Corp.
Our company focuses on risk stratification of patients for various illnesses especially cancer. Risk stratification is based on the 'sentinel' principle. This principle is formulated based on the fact that there are subtle changes that occur when a cancer develops that cannot be detected by conventional methods. The tumor secretes substances that can be detected in blood. Thus the detection of these substances that include interleukins, growth factors and other molecules in blood is termed bloodomics. This is the early detection of mRNA in blood for various diseases including cancer, heart disease and mental illness and gives a molecular signature of the disease.

BioNexus Gene Lab Corporation (BGLC) was incorporated in the State of Wyoming on May 12, 2017. On June 1, 2017, we acquired all of the outstanding capital stock of BGS Lab Sdn. Bdh., a Malaysian corporation (“Subsidiary”). The Subsidiary was incorporated in Malaysia on April 7, 2015. Our corporate structure is depicted below:

Panel of advisors ???
Prof Liew died in August 2019 ???

Professor Dato' Dr. Liew Choong-Chin

Professor Emeritus, Department of Laboratory Medicine & Pathobiology, University of Toronto and Harvard Medical School, Boston, USA

Lifetime Fellowship of the Royal Society of Medicine, London, UK

Dr.Charles H. Best Postdoctoral Fellowship

Fellowships awarded by Canadian Heart Foundation, Canadian Academy of Clinical Biochemistry and 14 Honorary Professorships at universities and institutions

James once mentioned that we own the intellectual property to the Sentinel Principle.
So why has this Malaysian company incorporated in the US and why were they featured as a speaker at the virtual Life Sciences Investment Forum December 17th 2020?

I know there was a company in Malaysia (BGS) that Liew was involved with. BGS is mentioned on the Bionexus website.

https://www.globenewswire.com/fr/news-release/2020/12/14/2144705/0/en/Bionexus-Gene-Lab-Corp-to-Webcast-Live-at-Life-Sciences-Investor-Forum-December-17th.html

https://www.bionexusgenelab.com/